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Abstract Recently, we showed that the amino acid at position 
61 in TMl of human P-glycoprotein is important in deciding the 
substrate specificity of this protein. In this work, we investigated 
whether the amino acids other than His61 in TMl of P-gly-
coprotein are also essential in the function of this protein. Nine 
amino acids residues, from Ala57 to Leu65 in TMl, were 
independently substituted to Arg, and analyzed the drug 
resistance of cells stably expressing each of these mutant 
P-glycoproteins. The mutant P-glycoproteins He80 -> Arg, 
His61 -> Arg, Ala63 -> Arg, Gly64 -> Arg, and Leu65 -> Arg were 
normally processed and expressed in the plasma membrane. 
Substrate specificities of mutant P-glycoproteins Gly64 -> Arg 
and Leu65 -> Arg were quite different from that of the wild type, 
and similar to that of the His61 -> Arg mutant, while the 
He60 -> Arg and Ala63 -> Arg mutant P-glycoproteins showed 
similar substrate specificities to that of the wild-type P-gly-
coprotein, suggesting that not only the amino acid residue at 
position 61 but also those at position 64 and 65 are also 
important in deciding the substrate specificity of P-glycoprotein. 
These three amino acids His61, Gly84, and Leu85 would form a 
compact region on an a-helix arrangement of TMl. These 
results suggest that a region consisting of His61, Gly64, and 
Leu85 in TMl would participate in the formation of the 
recognition site for substrates of P-glycoprotein. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
P-Glycoprotein, a member of ABC superfamily of trans-
porters, is an active transporter which utilizes the energy of 
ATP hydrolysis to pump cytotoxic drugs out of cells, [1,2]. 
P-Glycoprotein can recognize and transport so broad range of 
structurally dissimilar compounds that its overexpression con-
fers cells multidrug resistance. However, the mechanism by 
which P-glycoprotein can recognize such structurally diverse 
compounds remains to be elucidated. To improve our under-
standing of the molecular mechanism of P-glycoprotein, it is 
necessary to identify amino acid residues involved in the rec-
ognition and transport of its substrates. A number of amino 
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acid that modulate substrate specificity of P-glycoprotein have 
been identified. They have been located in transmembrane 
domain (TM) 4 [3], TM6 [4-6], TM10 [3], TM11 [7-9], 
TM12 [5], and the first [10-12], second, and fourth cytoplas-
mic loops [12]. The residues located in these transmembrane 
domains have been considered to be involved in the binding 
and transporting mechanisms of P-glycoprotein. However, no 
amino acid has been identified to be directly involved in the 
substrate recognition. 
We recently demonstrated that the replacements of His61, 
which is in the middle of TMl of P-glycoprotein, by other 
amino acids altered the drug resistance profile of P-glycopro-
tein [13]. Especially, the replacement of His61 by amino acids 
with bulkier side chain than His altered the drug resistance 
profiles drastically. It appears that, as far as the drugs we 
examined, there is an inverse relationship between the size 
of the side chain of the amino acid at position 61 and the 
molecular weight of preferred substrates. These results suggest 
that the amino acid residue at position 61 or the region con-
taining this residue plays a key role in deciding the preferen-
tial molecular size of the substrates, which have been sug-
gested to be one of the important determinants for 
substrates to interact effectively with P-glycoprotein [14,15]. 
The cystic fibrosis transmembrane conductance regulator 
(CFTR) is a chloride channel whose inherited malfunctions 
causes cystic fibrosis [16,17]. CFTR also belongs to the 
ABC superfamily, and the predicted topology of it, with the 
exception of the R domain, resembles that of P-glycoprotein. 
In CFTR, substitution and modification of amino acids in 
TMl were reported to alter the relative anion permeability 
sequence of the channel [18], and it was suggested that three 
amino acid residues in TMl are involved in forming part of 
the channel lining [19]. If the amino acid at position 61 of 
P-glycoprotein is involved in the formation of the recognition 
site for substrates, it would be expected that the amino acids 
located near His61 are also involved in the formation of the 
substrate recognition site and the mutations to those amino 
acids change the substrate specificity of P-glycoprotein. Then, 
nine amino acids residues, from Ala57 to Leu6° in TMl, were 
independently substituted to Arg, and analyzed the drug re-
sistance of cells stably expressing each of these mutants of 
P-glycoprotein. 
2. Materials and methods 
2.1. Materials 
Vinblastine (Vbl), colchicine (Col), and adriamycin (Adr) were pur-
chased from Wako Pure Chemical Industries, Ltd. VP16 (etoposide) 
was from Sigma. Monoclonal antibody C219 was from Centocor. 
2.2. Site-directed mutagenesis 
Oligonucleotides were synthesized to generate the appropriate sub-
stitutions. The manufacturer's mutagenesis procedure (Sculptor in vi-
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tro mutagenesis system, Amersham) was used to replace amino acids 
in TM1. Mutations were confirmed by DNA sequencing. 
2.3. Transfection and drug resistance assay 
The procedures of propagation of human cultured cells KB3-1 and 
of transfection by MDR1 expression vectors and its mutated variants 
were as described previously [13]. After cells were first selected in the 
presence of 0.8 mg/ml geneticin (G418) for 10 days, the obtained mass 
populations of geneticin-resistant colonies were selected by Vbl (5 ng/ 
ml) or Col (10 ng/ml). From transformant cells that could be resistant 
to Vbl and/or Col, the author obtained cells expressing a readily 
detectable amount of mutant P-glycoprotein by further selection 
with stepwise increasing concentrations of Vbl. Cells transfected by 
He60 -> Arg, or Ala63 -> Arg cDNA were selected with stepwise increas-
ing concentrations (10, 20, 40 ng/ml) of vinblastine and finally main-
tained in 30 ng/ml Vbl. Cells transfected with Gly64 —> Arg, or 
Leu65 -> Arg cDNAs were selected with stepwise increasing concentra-
tions (5, 10, 20 ng/ml) of vinblastine and finally maintained in 20 ng/ 
ml vinblastine. The IC50 (the drug concentration that inhibits cell 
growth by 50%) was measured by a colorimetric assay using 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) from 
dose-response curves for increasing concentrations of Vbl, Col (0-
300 ng/ml), VP16 (0-6 mg/ml), and Adr (0-900 ng/ml). 
2.4. Immunoblotting 
Membrane proteins were prepared as described previously [20] and 
resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
7% gels. Immunoblotting was done as described previously [20]. 
3. Results 
To elucidate the function of TM1 of P-glycoprotein further, 
we replaced the amino acid residues from Ala57 to Leu65, 
which are rather small and neutral amino acids, in TM1 in-
dependently by Arg, a bulky and basic amino acid, and in-
vestigated whether each of Arg substitutions altered the sub-
strate specificity of P-glycoprotein as the substitution at His61. 
In the previous study, we showed that the replacements of 
His61 by Arg changed the substrate specificity of P-glycopro-
tein drastically [13]. It reduced resistance to vinblastine (Vbl) 
and adriamycin (Adr), and increased resistance to colchicine 
(Col) and VP16, resulting in a resistance order of 
Co l>VP16~Vbl>Adr , while that of the wild type was 
Vbl>Adr = Col>VP16. 
Each mutant or the wild-type MDR1 cDNA was intro-
duced into the drug-sensitive human carcinoma cells KB3-1 
with an expression vector, in which the MDR1 cDNA was 
fused to the neoR gene with a IRES, same as used previously 
[13]. Cells were first selected in the presence of 0.8 mg/ml 
geneticin (G418) for 10 days. To assess functionality of the 
mutants, the mass populations of geneticin-resistant colonies 
obtained were selected by Vbl (5 ng/ml) or Col (10 ng/ml). 
From cells transfected with the wild type and He60 —> Arg, 
His61 -> Arg, Ala63 -> Arg, Gly64 -> Arg, or Leu65 -> Arg mu-
tant cDNA, both Vbl- and Col-resistant colonies were ob-
tained (Fig. 1). Cells transfected with the wild-type P-glyco-
protein cDNA yielded slightly more resistant colonies in the 
presence of Vbl (5 ng/ml) than in the presence of Col (10 ng/ 
ml). In contrast, cells transfected with mutants His61 -> Arg 
slightly more resistant colonies in the presence of Col than 
in the presence of Vbl. Noticeably, cells transfected with mu-
tant Gly64 -> Arg or Leu65 -> Arg yielded comparable number 
of Col-resistant colonies, but much less Vbl-resistant colonies, 
suggesting that the substrate specificities of these two mutants 
were altered from that of the wild type. To examine this 
possibility, we first obtained cells expressing a readily detect-
able amount of these five mutant P-glycoproteins by further 
selection with stepwise increasing concentrations of Vbl as 
described in Materials and Methods. Relative resistance to 
Vbl {5 ng/ml) 
Col(10ng/ml)| 
Vbl (5 ng/ml) 
Col (10 ng/ml) 
Fig. 1. Drug survival characteristics of geneticin-resistant mass populations of transfected cells. 1.0X105 cells from mass populations of geneti-
cin-resistant cells stably transfected with either wild-type or mutant P-glycoprotein cDNAs, or untransfected KB3-1 control cells were plated in 
medium containing 5.0 ng/ml vinblastine or 10.0 ng/ml colchicine in 6-well plates. Plates were mcubated for 7 days, stained with crystal violet 
(0.4% in methanol), and photographed. 
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Fig. 2. Immunoblots of membrane proteins from cells stably ex-
pressing wild-type and mutant P-glycoproteins. Membrane proteins 
were obtained from stable transformants maintained in 20 ng/ml 
vinblastine for mutants Gly64 -»Arg and Leu65 -> Arg, or 30 ng/ml 
vinblastine for wild type and the other mutants. Twenty u.g of mem-
brane proteins were resolved on a 7% SDS-PAGE gel and reacted 
with the monoclonal antibody C219 as a probe for P-glycoprotein. 
The arrow indicates the position of the 170-kDa mature form of 
P-glycoprotein. 
and processing to the plasma membrane of P-glycoprotein. 
We also failed to detect the mature form of P-glycoprotein, 
when Ala57 -> Arg, Ala58 -> Arg, Ile59->Arg, and Gly62 -> Arg 
mutant cDNAs were transiently expressed in HEK 293 cells 
(data not shown). These results suggested that these Arg mu-
tations severely interfered with the proper processing of P-gly-
coprotein. 
The drug-resistance profiles of the cells expressing 
He60 -> Arg, His61 -»Arg, Ala63 -»Arg, Gly64 -> Arg, and 
Leu65 -> Arg mutant P-glycoproteins were investigated by 
comparing their relative resistance to Vbl, Col, VP16, and 
Adr (Fig. 3). The drastic alterations in the drug resistance 
profile were observed with Gly64 -> Arg or Leu65 -> Arg mu-
tant as well as His61 -»Arg mutant. The cells expressing these 
two mutant P-glycoproteins were more resistant to Col than 
Vbl, and showed the increased resistance to VP16, like cells 
expressing His61 -> Arg mutant P-glycoprotein, while cells ex-
pressing the wild-type P-glycoprotein were more resistant to 
Vbl than Col, and showed low resistance to VP16. In contrast, 
the resistance profile of He60 -»Arg or Ala63 -> Arg mutant 
P-glycoprotein did not altered much from that of the wild 
type. These results suggest that the amino acid residues at 
positions 61, 64, and 65 have similar characteristic in deciding 
the substrate specificity. 
4. Discussion 
Vbl and Col of cells stably expressing mutant P-glycoproteins 
described below were as expected from the ratio of Vbl- and 
Col-resistant colonies emerging from geneticin-resistant cells 
(Fig. 1), suggesting that the stepwise selection with Vbl did 
not alter the resistance profiles conferred by mutant P-glyco-
proteins. The membrane fractions prepared from these trans-
fectants were subjected to immunoblot with the anti-P-glyco-
protein monoclonal antibody C219 (Fig. 2). From each of 
membrane fraction, a band migrating at about 170 kDa 
was detected, indicating that He60 -> Arg, His61 -»Arg, 
Ala63 -»Arg, Gly64 -»Arg, and Leu65 -> Arg mutant P-glyco-
proteins were normally processed and expressed in the plasma 
membrane. The difference in the level of expression of the 
wild type and the mutant P-glycoproteins was within a 
2-fold limit. KB3-1 host cells did not express the endogenous 
MDR1 gene, or the transcriptional activation of the endoge-
nous MDR1 gene did not occur even when the cells are main-
tained in the medium containing Vbl for several months, be-
cause the sequence of the wild-type P-glycoprotein was not 
found in the RT-PCR products from cells which were selected 
by Vbl after mutant MDR1 cDNAs were introduced (data 
not shown). Hence the drug-resistance profiles of the stable 
mutant cell lines are considered to represent substrate specif-
icities of the transfected mutant P-glycoproteins. 
However, from cells transfected with Ala57 -> Arg, 
Ala58 -> Arg, He59 -> Arg, or Gly62 -> Arg mutant cDNA, no 
Vbl- or Col-resistant colonies were obtained (Fig. 1). It was 
reported [21] that no Vbl- or Col-resistant colonies were 
obtained from cells transfected with either Gly54 -> Val, 
Ala58 -> Leu, or Gly62 -> Val mutant P-glycoprotein cDNA, 
and that the major products from these three mutant cDNAs 
were protein with an apparent mass of 150 kDa when their 
cDNAs were transiently expressed in HEK 293 cells, suggest-
ing that these mutations in TMl affected the proper folding 
In this study, we examined whether the substitution of ami-
no acids near His61 in TMl affect substrate specificity of 
P-glycoprotein. Amino acid residues from Ala57 to Leu65 in 
TMl were independently replaced by Arg, and stable trans-
formants expressing each mutant P-glycoprotein were tried to 
be established. The mutant P-glycoproteins, in which either 
He60, Ala63, Gly64, or Leu65 was replaced by Arg were success-
fully expressed in the plasma membrane of KB3-1 cells and 
were functional as drug transporters as the His61 mutants. The 
substrate specificities of Gly64 -»Arg and Leu65 -> Arg mutant 
P-glycoproteins were quite different from that of the wild 
type, and similar to that of His61 -»Arg mutant, while He60 
and Ala63 -> Arg mutant P-glycoproteins showed similar sub-
strate specificities to that of the wild-type P-glycoprotein. 
From the previous work [13], it was suggested that the size 
of the side chain of the residue at position 61 would play a 
key role in deciding the preferential molecular size of the 
substrates, which have been suggested to be one of the im-
portant determinants for substrates to interact effectively with 
P-glycoprotein [14,15]. The similarity among the substrate 
specificities of Gly64 -> Arg, Leu65 -> Arg, and His61 -> Arg 
mutant P-glycoproteins suggest that the amino acid residues 
at position 64 and 65 are also important in deciding the sub-
strate specificity. 
Although all the mutant P-glycoproteins in which His61 was 
replaced by each of other 19 amino acids were properly sorted 
to the plasma membrane and functional as drug [13], the 
mutant P-glycoproteins, in which either Ala57, Ala58, He59, 
or Gly62 was replaced by Arg, could not confer cells either 
Vbl- or Col-resistance. TMl of P-glycoprotein has been sug-
gested to be important for the formation of a functional con-
figuration, because the mutations to Gly54, Ala58, and Gly62 in 
TMl affected the proper folding and altered overall activity of 
P-glycoprotein [21]. It is most likely that replacement of Ala57, 
Ala58, He59, or Gly62 by Arg also affects the proper folding 
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Fig. 3. The drug resistance profiles of cells stably expressing wild-type or mutant P-glycoprotein. Relative resistance was calculated by compar-
ing the IC50 (the drug concentration necessary to inhibit cell growth by 50%) for each stably transfected type of cells expressing the wild-type 
or mutant P-glycoprotein to the IC50 of the host cell KB3-1. Each value is the mean of three separate experiments. The IC50 for KB3-1 was 
1.20 ng/ml for vinblastine (Vbl), 4.60 ng/ml for colchicine (Col), 176.0 ng/ml for VP16, and 9.88 ng/ml for adriamycin (Adr). 
and processing of P-glycoprotein. All together, these results 
suggest that some residues in TM1 would be important for the 
formation of a functional configuration and mutations to 
them would affect the proper folding and overall activity of 
P-glycoprotein. 
According to the predicted model for secondary structure of 
human P-glycoprotein [22,23], supported by several experi-
ments [21,24], it has been assumed that the secondary struc-
ture of the transmembrane domains of P-glycoprotein are 
a-helical. If it is a case, three amino acids His61, Gly64, and 
Leu65, mutations of which had similar effects on the substrate 
specificity, would form an compact region on an oc-helix ar-
rangement of TM1 (Fig. 4). On the other hand, He60 and 
Ala63, mutations of which did not greatly alter the drug re-
sistance profiles of P-glycoprotein, would face away from this 
region on an ce-helix arrangement. From these results, it is 
assumed that a region consisting of His61, Gly64, and Leu65 
in TM1 would participate in the formation of recognition site 
for substrates of P-glycoprotein. The substrate specificities of 
the Gly64 -> Arg and Leu65 -> Arg mutants were similar to, but 
not exactly same with that of the His61 -> Arg mutant. The 
cells expressing Gly64 -> Arg or Leu65 -> Arg mutant were 
more resistant to VP16 than to Vbl, while cells expressing 
the His61-* Arg mutant were more resistant to Vbl than to 
VP16 (Fig. 3). These results suggest that three amino acids, 
His61, Gly64, and Leu65 interact with substrates in different 
ways. Furthermore, Ala58, He59, and Gly62, mutations of 
which abolished the function of P-glycoprotein, would face 
the other side on an oc-helix arrangement of TM1. The region 
consisting of Ala58, He59, and Gly62 could be involved in the 
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Fig. 4. Helical wheel representation of the residues from Ala57 to 
Leu65 in TM1. The helical wheel is viewed from its C-terminus (the 
extracellular side) (A) and is viewed from a side, to which His61, 
Gly64, and Leu65, mutations of which drastically altered the sub-
strate specificity of P-glycoprotein, would face. Amino acid residues 
are indicated in single-letter code followed by position number. Res-
idues, mutations of which to Arg drastically altered the substrate 
specificity, are indicated with white letters in black (His61) or dark 
gray (Gly64, and Leu65) backgrounds. Residues, mutations of which 
to Arg did not much alter the substrate specificity (He60 and Ala63), 
are indicated with black letters in gray backgrounds. Residues, mu-
tations of which to Arg abolished the function of P-glycoprotein, 
are indicated with black letters in white backgrounds. 
formation of framework of P-glycoprotein, such as in the 
interaction between transmembrane cc-helices. 
In C F T R , it was suggested that three residues in T M 1 par-
ticipate in the formation of channel, through which ions 
would move across the membrane [19]. It may be presumed 
that three amino acids, His6 1 , Gly64 , and Leu6 5 , in P-glyco-
protein also face to a pore or a cavity like C F T R , where these 
amino acids form a part of the substrate recognition site. It is 
interesting that a region in T M 1 , not only in C F T R but also 
in P-glycoprotein, could be involved in the interaction with 
substrate. P-Glycoprotein and C F T R , both members of the 
A B C superfamily, might share a similar functional structure 
in spite of the difference in their functions as a transporter and 
an ion channel. 
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